Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Grupo Espanol Multidisciplinario del Cancer Digestivo
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01285778CT.gov Vectibix for the Treatment of Anal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anal Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Panitumumab (this asset) | Grupo Espanol Multidisciplinario del Cancer Digestivo | P2 | B · 57 |
| Fluorouracilum | Columbia University | P2 | BB |
| Nivolumab | National Cancer Institute (NCI) | P3 | BB |
| Carboplatin | Fudan University | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BB |
| Atezolizumab | Oncolytics Biotech | P2 | B |
| e7 tcr-t cells | Christian Hinrichs | P2 | B |
| Toripalimab | Sun Yat-sen University | P2 | B |
| Rigosertib | Traws Pharma, Inc. | P2 | B |
+31 more in the Anal Squamous Cell Carcinoma cohort
Other indications for Panitumumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P2 | BBB · 73 |
| Colorectal Cancer | — | P3 | BB · 68 |
| Rectal Carcinoma | — | P2 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Panitumumab in Anal Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/panitumumab-anal-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →